Received: 27 July 2022
Accepted: 11 November 2022
First Online: 23 November 2022
: Institutional review board (IRB) approval covering patient data contained in the OPERA<sup>®</sup> database was received from Advarra IRB; a waiver of informed consent and authorization for the use of protected health information for patient data was granted (Pro00023648). IRB approval from Advarra IRB was also received for survey data collected from AIDS Healthcare Foundation (AHF) workforce members (i.e., healthcare providers and other clinic staff members) (Pro00037143). Signed, informed consent was required and obtained from AHF workforce members willing to receive study surveys; completion of surveys was voluntary. The study was conducted in accordance with HIPAA and HITECH requirements, which expand upon the ethical principles detailed in the 1964 Declaration of Helsinki.
: Not applicable.
: MBW has participated in post-conference advisory boards for the Conference on Retroviruses and Opportunistic Infections (CROI) and International AIDS Conference (IAC) and serves as a principal investigator on ViiV Healthcare clinical trials but does not receive personal compensation for this work, which goes directly to the AIDS Healthcare Foundation. MBW is also a member of the Epidemiology and Clinical Advisory Board for Epividian, Inc. RPW, LB, JSF, and GPF are employed by Epividian, Inc.; Epividian has had research funded by the AIDS Healthcare Foundation, EMD Serono, Gilead Sciences, Janssen Pharmaceutica, Merck & Co., Theratechnologies Inc., and ViiV Healthcare. CU, QC, MP, and CM have no conflicts of interest to declare. TE is employed by ViiV Healthcare and holds stocks and shares in GSK as part of their employment.